...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease.
【24h】

Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease.

机译：细胞因子和抗细胞因子疗法可治疗哮喘和过敏性疾病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Until recently, the only controller treatment for chronic asthma has been corticosteroids. However, identification of specific effector molecules in asthma has led to targeting of specific pathways by using cytokines and cytokine inhibitors. Administration of a monoclonal blocking antibody against IgE has been shown to be highly efficacious in severe allergic asthma, but blockade of eosinophils using anti-IL-5 monoclonal antibodies has no clinical benefit. In more severe asthma, blockade of TNF-alpha using the decoy etanercept has revealed efficacy in a small open study suggesting that Th-1 in addition to Th-2 pathways are important as the disease adopts a more severe phenotype. It is likely that asthma is not a single disease but a group of disorders which differ in the relative contribution of specific pathophysiological pathways.
机译：直到最近，治疗慢性哮喘的唯一控制药物还是皮质类固醇。但是，哮喘中特定效应分子的鉴定已导致通过使用细胞因子和细胞因子抑制剂靶向特定途径。已经证明，在严重的过敏性哮喘中，抗IgE单克隆抗体的给药非常有效，但是使用抗IL-5单克隆抗体阻断嗜酸性粒细胞没有临床益处。在更严重的哮喘中，使用诱饵依那西普阻断TNF-α的效果在一项小型开放研究中显示出疗效，这表明Th-1除Th-2途径外也很重要，因为该疾病采用了更为严重的表型。哮喘可能不是单一疾病，而是一组在特定病理生理途径相对贡献方面不同的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号